The total number of records retrieved from this search are 21. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1264	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration3 MOI	In-vitro result20% cell viablity observed after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1265	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.3 MOI	In-vitro result25% cell viablity after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1266	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.03 MOI	In-vitro result40% cell viablity after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1267	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.003 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1268	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration3 MOI	In-vitro resultNo cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1269	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.3 MOI	In-vitro resultNo cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1270	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.03 MOI	In-vitro result10% cell viabilty after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1271	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.003 MOI	In-vitro result40% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1272	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration3 MOI	In-vitro resultNo cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1273	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.3 MOI	In-vitro resultNo cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1274	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.03 MOI	In-vitro resultNo cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_1275	Virus nameHerpes simplex virus	Virus strainHSV-HF10	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationAttenuated strain of HSV	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineTohuku University, Japan	Origin of cell lineMurine melanoma cell line	Cell lineM3	Concentration of cell line2.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan Blue exclusion assay	In-vitro virus concentration0.003 MOI	In-vitro result7.4% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18226503
IDOV_2570	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result90% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2571	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result72.5% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2572	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result50.2% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2573	Virus nameAdenovirus	Virus strainSG600-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result28.2% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2574	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result87.2% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2575	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result68% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2576	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result45% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2577	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell line1000 cells	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result25% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2578	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for HCCLM3 cell line	In-vivo virus concentration2.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume from the onset of tretament and till the end of 42 days and increase in median survival time	Mode of deliveryIntratumoral	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271